INM Stock Overview
A clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.50 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$2.41 |
| Beta | 0.65 |
| 11 Month Change | 21.68% |
| 3 Month Change | 3.11% |
| 1 Year Change | -31.25% |
| 33 Year Change | -99.27% |
| 5 Year Change | -99.82% |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02Shareholder Returns
| INM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 28.2% | 0.8% | 1.0% |
| 1Y | -31.3% | 13.4% | 32.3% |
Return vs Industry: INM underperformed the US Pharmaceuticals industry which returned 14% over the past year.
Return vs Market: INM underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| INM volatility | |
|---|---|
| INM Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INM's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Eric Adams | www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
| INM fundamental statistics | |
|---|---|
| Market cap | US$3.89m |
| Earnings (TTM) | -US$6.82m |
| Revenue (TTM) | US$4.96m |
0.8x
P/S Ratio-0.6x
P/E RatioIs INM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INM income statement (TTM) | |
|---|---|
| Revenue | US$4.96m |
| Cost of Revenue | US$3.39m |
| Gross Profit | US$1.57m |
| Other Expenses | US$8.39m |
| Earnings | -US$6.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.49 |
| Gross Margin | 31.71% |
| Net Profit Margin | -137.42% |
| Debt/Equity Ratio | 0% |
How did INM perform over the long term?
See historical performance and comparison